Oracle Corp. (NYSE: ORCL) will spend $28.3 billion to acquire Cerner Corp., the two companies announced today. Cerner is a significant provider of digital information systems used within hospitals and health systems. Get the full story on our sister site Medical Design & Outsourcing.
Oracle Corp.
Oracle launches cloud-based mHealth clinical trial data collection system
Multinational computer tech company Oracle today announced the launch of its Oracle Health Sciences mHealth connector cloud service designed to aid clinical study teams in remotely collecting data from patient sensors, wearable and apps for use in clinical trials. The newly launched system is designed to improve the ease of collecting data from a number […]
The CFO shuffle continues for InVivo Therapeutics | Personnel Moves
InVivo Therapeutics (OTC:NVIV) is on its 3rd financial chief since August, saying it named Steven McAllister to replace interim CFO Gregory Perry.
Perry stepped down effective Dec. 30 to join an unnamed biotechnology company as its CFO, according to a press release.
Oracle turns up the heat on Thoratec sale
It’s time for implantable heart pump maker Thoratec Corp. (NSDQ:THOR) to throw in the towel and sell itself off, according to Oracle Investment Management.
Thoratec needs a more seasoned company to help it push past a period of sluggish growth, meaning that putting the cardiac assist device firm up for auction is best for shareholders, according to the activist investor group.
DOJ OKs Oracle’s Phase Forward buyout
Phase Forward Inc. (NSDQ:PFWD) is another step closer to merging with software giant Oracle Corp. (NSDQ:ORCL).
The U.S. Dept. of Justice gave the companies clearance to proceed with their $685 million deal, announced in April.
Phase Forward shareholders OK Oracle buyout
Shareholders of Phase Forward Inc. (NSDQ:PFWD) voted to approve a $685 million acquisition bid from Oracle Corp. (NSDQ:ORCL).
The Waltham, Mass.-based clinical trial data management firm also announced the dismissal of a lawsuit filed by stockholders, accusing the company and its management of breaching their fiduciary duties in agreeing to the merger and seeking to block the deal.
DOJ investigates Oracle’s Phase Forward buyout
The U.S. Dept. of Justice is investigating Oracle Corp.’s (NSDQ:ORCL) $685 million bid to acquire Phase Forward Inc. (NSDQ: PFWD), according to a filing with the Securities and Exchange Commission.
The Waltham, Mass.-based clinical trial data management provider said it received a “Request for Additional Information” May 27 from the Justice Dept., meaning an extension of the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, according to the filing.
Oracle to pay $685 million for Phase Forward
Oracle Corp. (NSDQ:ORCL) agreed to pay $17 per share in cash, or about $685 million, to acquire Phase Forward Inc. (NSDQ: PFWD).
The deal, expected to close in mid-2010, will see the Waltham, Mass.-based clinical trial data management provider integrated into the global health sciences division Oracle established in June 2008.
